1.
Nature
; 617(7962): 661-662, 2023 May.
Article
in English
| MEDLINE | ID: covidwho-2324354
2.
Nature
; 616(7958): 638-639, 2023 Apr.
Article
in English
| MEDLINE | ID: covidwho-2298172
3.
Nature
; 614(7949): 602-603, 2023 02.
Article
in English
| MEDLINE | ID: covidwho-2268180
4.
Nature
; 586(7827): 16-17, 2020 10.
Article
in English
| MEDLINE | ID: covidwho-2185679
Subject(s)
Clinical Trials as Topic , Coronavirus Infections/prevention & control , Drug Approval/legislation & jurisprudence , Drug Industry , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Politics , Research Personnel , Safety , Viral Vaccines/adverse effects , COVID-19 , COVID-19 Vaccines , Clinical Trial Protocols as Topic , Clinical Trials as Topic/ethics , Clinical Trials as Topic/methods , Clinical Trials as Topic/standards , Coronavirus Infections/epidemiology , Disclosure , Drug Industry/ethics , Drug Industry/legislation & jurisprudence , Drug Industry/standards , Humans , Myelitis, Transverse/etiology , Pneumonia, Viral/epidemiology , Public Opinion , Research Personnel/psychology , Sample Size , United Kingdom , United States , United States Food and Drug Administration/legislation & jurisprudence , Viral Vaccines/standards
5.
Nature
; 612(7941):619, 2022.
Article
in English
| ProQuest Central | ID: covidwho-2185686
6.
Nature
; 2022 Dec 05.
Article
in English
| MEDLINE | ID: covidwho-2151009
7.
Nature
; 580(7805): 573, 2020 04.
Article
in English
| MEDLINE | ID: covidwho-2133267
8.
Nature
; 2022 Nov 02.
Article
in English
| MEDLINE | ID: covidwho-2096653
9.
Nature
; 2022 Sep 15.
Article
in English
| MEDLINE | ID: covidwho-2028660
10.
Nature
; 609(7925): 20-21, 2022 09.
Article
in English
| MEDLINE | ID: covidwho-2016623
11.
Nature
; 609(7925): 18-19, 2022 09.
Article
in English
| MEDLINE | ID: covidwho-2000858
12.
Nature
; 608(7922): 258-260, 2022 08.
Article
in English
| MEDLINE | ID: covidwho-1991543
13.
Nature
; 580(7803): 311-312, 2020 04.
Article
in English
| MEDLINE | ID: covidwho-1972558
Subject(s)
Betacoronavirus/pathogenicity , Clinical Decision-Making , Coronavirus Infections/drug therapy , Coronavirus Infections/immunology , Interleukin-6/antagonists & inhibitors , Pneumonia, Viral/drug therapy , Pneumonia, Viral/immunology , Steroids/adverse effects , Steroids/therapeutic use , Uncertainty , Antibodies, Monoclonal, Humanized/pharmacology , Antibodies, Monoclonal, Humanized/therapeutic use , Betacoronavirus/drug effects , Betacoronavirus/immunology , COVID-19 , Coronavirus Infections/mortality , Coronavirus Infections/pathology , Humans , Immunosuppressive Agents/pharmacology , Immunosuppressive Agents/therapeutic use , Interleukin-6/immunology , Macrophages/drug effects , Macrophages/immunology , Pandemics , Physicians/psychology , Pneumonia, Viral/mortality , Pneumonia, Viral/pathology , Randomized Controlled Trials as Topic , SARS-CoV-2 , Steroids/administration & dosage , Steroids/pharmacology , T-Lymphocytes/drug effects , T-Lymphocytes/immunology
14.
Nature
; 607(7917): 20-21, 2022 07.
Article
in English
| MEDLINE | ID: covidwho-1931357
15.
Nature
; 2022 Jun 29.
Article
in English
| MEDLINE | ID: covidwho-1908134
16.
Nature
; 606(7916): 852-853, 2022 06.
Article
in English
| MEDLINE | ID: covidwho-1900462
17.
Nature
; 605(7910):417-418, 2022.
Article
in English
| ProQuest Central | ID: covidwho-1860317
18.
Nature
; 2022 May 13.
Article
in English
| MEDLINE | ID: covidwho-1852396
19.
Nature
; 604(7906): 412-413, 2022 04.
Article
in English
| MEDLINE | ID: covidwho-1773950
Subject(s)
COVID-19 , Clinical Trials as Topic , Africa , Drug Combinations , Humans , Lactams , Leucine , Nitriles , Proline , Ritonavir , SARS-CoV-2
20.
Nature
; 604(7904): 20-21, 2022 04.
Article
in English
| MEDLINE | ID: covidwho-1764151